These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33043582)

  • 1. New Subtype Proposed for Myelodysplastic Syndrome.
    Am J Med Genet A; 2020 Aug; 182(8):1854-1855. PubMed ID: 33043582
    [No Abstract]   [Full Text] [Related]  

  • 2. Clonal shifts in MDS - from SF3B1 to EZH2.
    Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
    Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and
    Martin-Cabrera P; Jeromin S; Perglerovà K; Haferlach C; Kern W; Haferlach T
    Haematologica; 2017 Apr; 102(4):e125-e128. PubMed ID: 28057736
    [No Abstract]   [Full Text] [Related]  

  • 4. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.
    Kanagal-Shamanna R; Hidalgo Lopez JE; Milton DR; Kim HR; Zhao C; Zuo Z; Janania Martinez M; Stingo F; Lee J; Luthra R; Jabbour EJ; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
    Am J Hematol; 2017 Aug; 92(8):E168-E171. PubMed ID: 28456995
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms.
    Chao MM; Thomay K; Goehring G; Wlodarski M; Pastor V; Schlegelberger B; Schindler D; Kratz CP; Niemeyer C
    Klin Padiatr; 2017 Nov; 229(6):329-334. PubMed ID: 29132164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Molecular Pathology of Myelodysplastic Syndrome.
    Haferlach T
    Pathobiology; 2019; 86(1):24-29. PubMed ID: 29791902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes.
    Komrokji R; Volpe V; Chan O; Al Ali N; Swoboda D; Kuykendall A; Padron E; Sallman DA
    Blood; 2021 Sep; 138(11):989-992. PubMed ID: 34036300
    [No Abstract]   [Full Text] [Related]  

  • 8. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.
    Singh S; Ahmed D; Dolatshad H; Tatwavedi D; Schulze U; Sanchi A; Ryley S; Dhir A; Carpenter L; Watt SM; Roberts DJ; Abdel-Aal AM; Sayed SK; Mohamed SA; Schuh A; Vyas P; Killick S; Kotini AG; Papapetrou EP; Wiseman DH; Pellagatti A; Boultwood J
    Leukemia; 2020 Sep; 34(9):2525-2530. PubMed ID: 32076118
    [No Abstract]   [Full Text] [Related]  

  • 9. Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.
    Nagata Y; Makishima H; Kerr CM; Przychodzen BP; Aly M; Goyal A; Awada H; Asad MF; Kuzmanovic T; Suzuki H; Yoshizato T; Yoshida K; Chiba K; Tanaka H; Shiraishi Y; Miyano S; Mukherjee S; LaFramboise T; Nazha A; Sekeres MA; Radivoyevitch T; Haferlach T; Ogawa S; Maciejewski JP
    Nat Commun; 2019 Nov; 10(1):5386. PubMed ID: 31772163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the outlook for myelodysplastic syndrome.
    Brower V
    J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
    [No Abstract]   [Full Text] [Related]  

  • 11. Myelodysplastic Syndrome Updated.
    Hasserjian RP
    Pathobiology; 2019; 86(1):7-13. PubMed ID: 30041243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.
    Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
    Leukemia; 2017 Sep; 31(9):1995-1997. PubMed ID: 28592886
    [No Abstract]   [Full Text] [Related]  

  • 13. Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple
    Lodé L; Ameur A; Coste T; Ménard A; Richebourg S; Gaillard JB; Le Bris Y; Béné MC; Lavabre-Bertrand T; Soussi T
    Haematologica; 2018 Jan; 103(1):e13-e16. PubMed ID: 29079597
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular mechanisms of myeloid malignancies].
    Matsui H
    Rinsho Ketsueki; 2021; 62(8):883-891. PubMed ID: 34497227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.
    Pollyea DA; Harris C; Rabe JL; Hedin BR; De Arras L; Katz S; Wheeler E; Bejar R; Walter MJ; Jordan CT; Pietras EM; Alper S
    Haematologica; 2019 Sep; 104(9):e388-e392. PubMed ID: 30846499
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).
    Tefferi A; Idossa D; Lasho TL; Mudireddy M; Finke C; Shah S; Nicolosi M; Patnaik MM; Pardanani A; Gangat N; Hanson CA; Ketterling RP
    Blood Cancer J; 2017 Dec; 7(12):658. PubMed ID: 29249799
    [No Abstract]   [Full Text] [Related]  

  • 18. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.
    Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Hellström-Lindberg E; Cazzola M; Wainscoat JS
    Leukemia; 2010 May; 24(5):1062-5. PubMed ID: 20182461
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute leukemia: a pediatric perspective.
    Downing JR; Shannon KM
    Cancer Cell; 2002 Dec; 2(6):437-45. PubMed ID: 12498712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
    Steensma DP; Wermke M; Klimek VM; Greenberg PL; Font P; Komrokji RS; Yang J; Brunner AM; Carraway HE; Ades L; Al-Kali A; Alonso-Dominguez JM; Alfonso-Piérola A; Coombs CC; Deeg HJ; Flinn I; Foran JM; Garcia-Manero G; Maris MB; McMasters M; Micol JB; De Oteyza JP; Thol F; Wang ES; Watts JM; Taylor J; Stone R; Gourineni V; Marino AJ; Yao H; Destenaves B; Yuan X; Yu K; Dar S; Ohanjanian L; Kuida K; Xiao J; Scholz C; Gualberto A; Platzbecker U
    Leukemia; 2021 Dec; 35(12):3542-3550. PubMed ID: 34172893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.